Clorox
CLX
$107.62
+1.85%
The Clorox Company is a leading manufacturer and marketer of consumer products across cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water filtration, and natural personal care. It operates as a portfolio-driven consumer staples giant, owning iconic household brands such as Clorox, Pine-Sol, Glad, Hidden Valley, Brita, and Burt's Bees. The current investor narrative centers on the company's ongoing recovery from past operational challenges, with recent financial results showing signs of stabilizing profitability and revenue trends, while the market debates the sustainability of its margin improvement and its ability to navigate persistent inflationary pressures and competitive dynamics in a post-pandemic environment.…
CLX
Clorox
$107.62
Related headlines
Investment Opinion: Should I buy CLX Today?
Rating: Hold. The core thesis is that CLX is a financially leveraged, slow-growth consumer staples company in the midst of a fragile operational recovery, where near-term risks and lack of positive catalysts outweigh its reasonable valuation and income yield.
Supporting this view are several data points: 1) Stagnant revenue growth (-0.77% YoY) limits upside, 2) A high forward P/E of 14.9x is reasonable but not compelling without growth acceleration, 3) A strong 4.06% dividend yield is supported by robust TTM FCF of $778M, and 4) Analyst sentiment is neutral/cautious with no recent upgrades, reflecting a wait-and-see stance. The stock's severe underperformance (-31.49% over 1 year) has priced in many challenges, but a clear catalyst for reversal is absent.
The thesis would upgrade to a Buy if the company demonstrates sustained quarterly revenue growth above 2-3% and maintains gross margins above 43%, signaling a durable turnaround. It would downgrade to a Sell if the debt-to-equity ratio escalates further above 9.0, liquidity deteriorates (current ratio below 0.8), or the dividend payout ratio exceeds 90%, threatening sustainability. Relative to its own challenged history and the defensive sector, the stock appears fairly valued, neither offering a deep-value margin of safety nor trading at an excessive premium.
Sign up to view all
CLX 12-Month Price Forecast
CLX is stuck in a neutral zone. Its high yield and improving margins offer defensive appeal, but these are counterbalanced by alarming leverage and no top-line growth. The path of least resistance appears to be sideways consolidation within a range, as the market awaits clearer signs of whether this is a stable cash cow or a value trap. The stance would upgrade to bullish on confirmation of sustained revenue growth and debt reduction, while a breakdown below the $96.66 support on deteriorating fundamentals would warrant a bearish view.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Clorox's 12-month outlook, with a consensus price target around $139.91 and implied upside of +30.0% versus the current price.
Average Target
$139.91
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$86 - $140
Analyst target range
Analyst coverage is limited, with only 6 analysts providing estimates, indicating this is not a heavily followed large-cap stock. The consensus sentiment is neutral to cautious, as evidenced by recent institutional ratings which are predominantly 'Hold', 'Neutral', or 'Equal Weight', with one 'Underperform'. The average target price is not explicitly provided in the data, so implied upside cannot be calculated. The target range for estimated EPS is between $7.94 and $8.56, showing a relatively tight spread of about 8%, which suggests a moderate level of uncertainty around near-term earnings projections. The pattern of recent analyst actions shows no upgrades or downgrades in the provided data, with all firms maintaining their existing ratings, reflecting a wait-and-see stance as the company executes its recovery plan. Limited coverage can lead to higher volatility and less efficient price discovery for the stock.
Bulls vs Bears: CLX Investment Factors
The evidence currently tilts bearish, driven by severe technical deterioration, stagnant revenue, and a highly leveraged balance sheet that overshadows improving margins and strong cash flow. The most important tension in the investment debate is whether the company's robust free cash flow generation and margin recovery can sustainably overcome its massive debt burden and reignite top-line growth. If margin improvements prove durable and translate to stronger earnings, the reasonable valuation could provide a floor. However, if revenue remains flat and interest expenses pressure profits, the high leverage could trigger further downside.
Bullish
- Strong Free Cash Flow Generation: The company generated $778 million in TTM free cash flow, providing a robust cushion to service its high debt and fund its dividend. This operational cash generation is a key strength, supporting a sustainable 4.06% dividend yield.
- Improving Gross Margin Trend: Gross margin improved to 43.16% in the latest quarter, up from 41.57% in the prior quarter. This sequential improvement suggests management is successfully navigating inflationary pressures and implementing cost-saving initiatives.
- Reasonable Forward Valuation: With a forward P/E of 14.9x, the stock trades at a discount to its trailing P/E of 18.3x, implying analyst expectations for earnings recovery. This valuation appears reasonable for a stable consumer staples company, especially given its recent price decline.
- Low Market Volatility Beta: The stock's beta of 0.645 indicates it is 35% less volatile than the broader market. This defensive characteristic can provide relative downside protection during broader market sell-offs, aligning with its consumer staples profile.
Bearish
- Severe Technical Downtrend & Weakness: The stock is down 31.49% over the past year and 16.52% in the past month, severely underperforming the S&P 500. Trading near 67% of its 52-week range indicates persistent selling pressure and a lack of positive momentum.
- Stagnant Revenue Growth: Recent quarterly revenue of $1.673 billion declined 0.77% year-over-year, and the multi-quarter trend shows volatility and lack of growth. This top-line stagnation challenges the narrative of a full recovery and limits earnings expansion.
- Highly Leveraged Balance Sheet: A debt-to-equity ratio of 8.97 indicates an extremely leveraged capital structure. This elevates financial risk, increases interest expense (latest quarter: $28M), and constrains strategic flexibility, especially in a higher-rate environment.
- Potential Liquidity Constraint: A current ratio of 0.84 suggests the company may have difficulty covering its short-term obligations with current assets. This is a concerning signal when combined with high debt levels and could pressure operations.
CLX Technical Analysis
The stock is entrenched in a pronounced downtrend, evidenced by a 1-year price change of -31.49% and a 6-month decline of -17.90%. With a current price of $101.14, it is trading at approximately 67% of its 52-week range (between $96.66 and $150.84), positioning it closer to its lows, which suggests a potential value opportunity but also reflects significant negative momentum and investor skepticism. Recent momentum shows a sharp deterioration, with the stock down 16.52% over the past month, starkly underperforming the S&P 500's -4.28% move, indicating severe relative weakness and a potential capitulation phase. This short-term acceleration of losses diverges from a slightly positive 3-month change of +0.29%, signaling the recent sell-off has erased the modest recovery seen earlier in the year. Key technical support is clearly defined at the 52-week low of $96.66, while resistance sits at the 52-week high of $150.84. A breakdown below $96.66 would signal a new leg down, whereas a sustained move above recent highs near $127 would be needed to suggest a trend reversal. The stock's beta of 0.645 indicates it is 35% less volatile than the broader market, which, while providing some downside cushion during market stress, has not prevented its severe underperformance.
Beta
0.65
0.65x market volatility
Max Drawdown
-35.5%
Largest decline past year
52-Week Range
$97-$144
Price range past year
Annual Return
-23.0%
Cumulative gain past year
| Period | CLX Return | S&P 500 |
|---|---|---|
| 1m | -7.1% | +0.4% |
| 3m | +1.3% | -2.0% |
| 6m | -10.4% | +4.1% |
| 1y | -23.0% | +23.9% |
| ytd | +6.7% | -0.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CLX Fundamental Analysis
Revenue growth remains stagnant, with the most recent quarterly revenue of $1.673 billion representing a slight year-over-year decline of -0.77%. The multi-quarter trend shows volatility, with revenue dipping from $1.908 billion in Q4 2024 to the current level, indicating persistent top-line challenges. The Health and Wellness segment, at $643 million, is the largest contributor in the latest period, but overall growth is lackluster. The company is profitable, posting net income of $157 million for the quarter, translating to a net margin of 9.38%. Gross margin improved to 43.16%, up from 41.57% in the prior quarter, suggesting some success in managing input costs. However, operating income of $241 million yields an operating margin of 14.41%, which, while positive, reflects ongoing pressure. The balance sheet shows significant leverage with a debt-to-equity ratio of 8.97, indicating a highly leveraged capital structure that elevates financial risk. Free cash flow generation is a relative strength, with TTM free cash flow of $778 million, providing some capacity to service debt and fund the dividend. The current ratio of 0.84 points to potential liquidity constraints in covering short-term obligations, which is a concern given the high debt load.
Quarterly Revenue
$1.7B
2025-12
Revenue YoY Growth
+0.00%
YoY Comparison
Gross Margin
+0.43%
Latest Quarter
Free Cash Flow
$778000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CLX Overvalued?
Given the positive net income, the primary valuation metric is the P/E ratio. The trailing P/E stands at 18.3x, while the forward P/E is lower at 14.9x, indicating the market expects earnings growth. The gap between the two suggests analysts anticipate a recovery in profitability. Compared to its own historical range, the current trailing P/E of 18.3x is below the extreme highs seen in recent quarters (e.g., 672.8x in Q3 2025) which were distorted by low earnings, and is more in line with levels seen in mid-2024. This positions the stock in a more normalized, mid-range valuation zone relative to its own history, neither signaling extreme optimism nor deep value. A direct industry average comparison is not available in the provided data, but the forward P/E of 14.9x appears reasonable for a stable, albeit slow-growing, consumer staples company with high leverage, suggesting the market has priced in the current challenges.
PE
18.3x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -98x~185x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are pronounced, primarily centered on an extremely leveraged balance sheet with a debt-to-equity ratio of 8.97. This high leverage, coupled with a current ratio of 0.84 indicating potential short-term liquidity constraints, creates a fragile financial structure. While TTM free cash flow of $778 million provides a buffer, the company's ability to consistently generate cash to service debt and fund its dividend (payout ratio 74.3%) is critical, especially if revenue growth remains stagnant, as seen in the recent -0.77% YoY decline.
Market & Competitive Risks include valuation compression for a stock that has already fallen 31.49% over the past year. Trading at a forward P/E of 14.9x, it is not egregiously valued, but persistent underperformance could lead to a de-rating if the recovery narrative falters. The stock's low beta of 0.645 offers some defensive characteristic, but it has failed to prevent severe relative weakness, as evidenced by its -53.69% relative strength versus the S&P 500 over one year. Competitive pressures and private label incursion in its core household product categories threaten market share and pricing power, potentially capping margin improvements.
Worst-Case Scenario involves a combination of failed margin initiatives, a recessionary drop in consumer spending on discretionary home care items, and rising interest rates further straining its debt service. This could lead to a dividend cut—shattering its 'aristocrat' status—and a severe loss of investor confidence. The realistic downside could see the stock re-test and break its 52-week low of $96.66, approaching levels implied by its max drawdown of -37.7%. From the current price of $101.14, this scenario presents a potential loss of approximately -4.4% to the immediate support, with further downside risk into the $80s if the financial structure comes under serious scrutiny.
FAQ
The key risks are, in order of severity: 1) Financial Risk: Extremely high leverage (Debt/Equity: 8.97) and a weak current ratio (0.84) create vulnerability to rising rates and economic downturns. 2) Operational Risk: Persistent revenue stagnation and inability to sustain recent margin improvements could pressure earnings. 3) Competitive/Market Risk: Intense competition and private label pressure could erode market share and pricing power in core categories. 4) Dividend Risk: While the payout ratio is 74.3%, a severe earnings downturn could threaten the company's 'Dividend Aristocrat' status, which is a key part of its investment narrative.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $105 and $120, as the company muddles through with flat revenue and modest margin improvement. The Bull Case (25% probability) targets $127 to $140, driven by successful execution of the turnaround, revenue growth, and debt reduction. The Bear Case (15% probability) warns of a drop to $85-$96.66 if operational performance deteriorates and leverage concerns intensify. The most likely outcome is the Base Case, reflecting the current lack of catalysts to break the stock out of its downtrend, balanced by its reasonable valuation and high yield providing a floor.
CLX appears fairly valued relative to its current prospects. The forward P/E of 14.9x is a discount to the trailing P/E of 18.3x, reflecting expectations for modest earnings improvement. This multiple is reasonable for a stable, albeit leveraged, consumer staples company with no growth. The stock is not cheap on a price-to-book basis (46.2x) due to low equity from high debt, but this is a distorted metric. The market is pricing in a slow recovery with persistent challenges, not a premium for growth or operational excellence. Therefore, it is neither deeply undervalued nor egregiously overvalued.
CLX is a conditional buy, primarily for income-focused investors who can tolerate high financial risk. The 4.06% dividend yield is attractive and appears sustainable given the $778M in TTM free cash flow. However, the stock carries significant baggage, including a debt-to-equity ratio of 8.97 and stagnant revenue growth (-0.77% YoY). It is not a good buy for growth investors or those seeking low-risk stability. A patient investor betting on a slow operational recovery might find value at the current forward P/E of 14.9x, but should be prepared for volatility and further downside if the turnaround falters.
CLX is more suitable for a long-term investment horizon of 3-5 years, but only for investors whose primary goal is income and who believe in the long-term durability of its brands. The short-term outlook is clouded by operational uncertainty and technical weakness, making it a poor candidate for trading. The low beta of 0.645 suggests it is less volatile than the market, which aligns with a longer-term, buy-and-hold income strategy. However, given the high leverage, investors must be prepared for a bumpy ride and should have a horizon long enough to allow management's recovery plan to potentially bear fruit or for the debt burden to be gradually reduced.